The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated. METHODS: In a cohort study, we included 271,174 patients with type 2 diabetes who were registered in the Swedish National Diabetes Register and matched them with 1,355,870 controls on the basis of age, sex, and county. We assessed patients with diabetes according to age categories and according to the presence of five risk factors (elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, albuminuria, smoking, and elevated blood pressure). Cox regression was used to study the excess risk of outcomes (death, acute myocardial infarction, stroke, and hospitalization for heart failure) associated with smoking and the number of variables outside target ranges. We also examined the relationship between various risk factors and cardiovascular outcomes. RESULTS: The median follow-up among all the study participants was 5.7 years, during which 175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of outcomes decreased stepwise for each risk-factor variable within the target range. Among patients with diabetes who had all five variables within target ranges, the hazard ratio for death from any cause, as compared with controls, was 1.06 (95% confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial infarction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 (95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside the target range was the strongest predictor of stroke and acute myocardial infarction; smoking was the strongest predictor of death. CONCLUSIONS: Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when all major cardiovascular risk factors are treated to within the target ranges, people with type 2 diabetes have risk of death, MI, or stroke similar to that of the general population (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among persons with type 2 diabetes (T2D), cardiovascular risk and mortality are dependent on the number of uncontrolled risk factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the evidence from prospective intervention studies to support comprehensive ASCVD risk factor reduction, a large cohort study confirmed no or only marginally increased mortality, MI, and stroke risk compared with the general population when all major cardiovascular risk factors are managed to goal levels in people with type 2 diabetes (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertriglyceridemia is indirectly linked with changes in HDL-C and LDL-C composition that are conducive to accelerated atherogenesis.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In persons with fasting triglycerides of 200 to 499 mg/dL, despite tight adherence to a healthy diet (to include reduced intake of simple carbohydrates and avoidance of fruit juices and alcohol) and optimized glycemia control, prescribe statin therapy to the maximum tolerated dose to achieve goals for non-HDL-C or apo B, since all apo B–containing particles are potentially atherogenic.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To date, aside from icosapent ethyl, fish oil therapy has not been shown to prevent CV adverse events.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No RCT has yet been reported to investigate the benefit of reducing severe (>500 mg/dL) or moderate (>200 mg/dL) hypertriglyceridemia to prevent CVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite these newer therapies, the risk of kidney failure remains high, particularly in those whose risk factors are insufficiently controlled.6,7”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with advanced disease, e.g.T2DM and established microalbuminuria, an intensive, target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) resulted in 50% fewer microvascular and macrovascular events after 7.8 years of follow-up.361”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [361]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 999
Trends of mortality in diabetic patients in Taiwan: A nationwide survey in 2005–2014
Li, H., Wu, Y., Tu, S., Hwu, C., Liu, J., & Chuang, L. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.07.008 · Cited by 37
Polovina, M. M., Lund, L. H., Đikić, D., Petrović‐Đorđević, I., Krljanać, G., Milinković, I., Veljić, I., Piepoli, M. F., Rosano, G. M. C., Ristić, A. D., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1666 · Cited by 37
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab147 · Cited by 43
Norhammar, A., Bodegård, J., Eriksson, J. W., Haller, H. G., Linssen, G. C. M., Banerjee, A., Karasik, A., Mamouris, P., Tangri, N., Taveira‐Gomes, T., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14698 · Cited by 36
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Cahn, A., Raz, I., Leiter, L. A., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Bhatt, D. L., McGuire, D. K., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2492 · Cited by 38
Self-citationMoazzeni, S. S., Ghafelehbashi, H., Hasheminia, M., Parizadeh, D., Ghanbarian, A., Azizi, F., & Hadaegh, F. (2020) · BMC Public Health · doi:10.1186/s12889-020-09595-4 · Cited by 35
Hao, R. C., Myroniuk, T. W., McGuckin, T., Manca, D. P., Campbell-Scherer, D. L., Lau, D., & Yeung, R. O. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01731-w · Cited by 37
Bonora, B. M., de Kreutzenberg, S. V., Avogaro, A., & Fadini, G. P. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0910-5 · Cited by 35
Diabetes and stroke: An important complication
Bloomgarden, Z. T., & CHILTON, R. J. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13142 · Cited by 38
Sönmez, A., Demirci, İ., Haymana, C., Taşçı, İ., Dağdelen, S., Salman, S., Ata, N., Sahin, I., Emral, R., Çakal, E., et al. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13171 · Cited by 35
Memarian, E., Hart, L. M. ‘., Slieker, R. C., Lemmers, R. F. H., van der Heijden, A. A. W. A., Rutters, F., Nijpels, G., Schoep, E., Lieverse, A. G., Sijbrands, E. J. G., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002345 · Cited by 36
Mancini, G. B. J., Maron, D. J., Hartigan, P. M., Spertus, J. A., Kostuk, W. J., Berman, D. S., Teo, K. K., Weintraub, W. S., & Boden, W. E. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.067 · Cited by 33
Sacco, S., Foschi, M., Ornello, R., Santis, F. D., Pofi, R., & Romoli, M. (2024) · Diabetologia · doi:10.1007/s00125-024-06146-z · Cited by 41
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes
Ji, L., Ma, J., Ma, Y., Cheng, Z., Gan, S., Yuan, G., Liu, D., Li, S., Liu, Y., Xue, X., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.62185 · Cited by 40
Ding, M., Shi, R., Du, Y., Chang, P., Gao, T., De, D., Chen, Y., Li, M., Li, J., Li, K., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.006 · Cited by 34
Yamada, M. H., Fujihara, K., OSAWA, T., Yamamoto, M., Kaneko, M., Kitazawa, M., Matsubayashi, Y., Yamada, T., YAMANAKA, N., Seida, H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00168 · Cited by 34
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 34
Ram, E., Sternik, L., Klempfner, R., Iakobishvili, Z., Fisman, E. Z., Tenenbaum, A., Zuroff, E., Peled, Y., & Raanani, E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01069-6 · Cited by 34
Wang, T., Wu, J., Dong, W., Wang, M., Zhong, X., Zhang, W., Dai, L., Xie, Y., Liu, Y., He, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60459 · Cited by 33
Bjornstad, P., Greasley, P. J., Wheeler, D. C., Chertow, G. M., Langkilde, A. M., Heerspink, H. J. L., & van Raalte, D. H. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.003 · Cited by 41
Gyldenkerne, C., Knudsen, J. S., Olesen, K. K. W., Sørensen, H. T., Bøtker, H. E., Thomsen, R. W., & Mæng, M. (2021) · Diabetes Care · doi:10.2337/dc21-0383 · Cited by 34
Sun, H., Wu, Z., Nie, X.-W., Wang, X., & Bian, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.651884 · Cited by 35
Patel, K. V., Segar, M. W., Lavie, C. J., Kondamudi, N., Neeland, I. J., Almandoz, J. P., Martin, C. K., Carbone, S., Butler, J., Powell‐Wiley, T. M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055830 · Cited by 34
Sueldo, M. D., Rivera, M. A. M., Sanchez-Zambrano, M. B., Zilberman, J. M., Múnera, A. G., Paniagua, M., Campos-Alcántara, L., Almonte, C., Paix-Gonzales, A., Anchique-Santos, C. V., et al. (2022) · Archivos de cardiología de México · doi:10.24875/acm.22000071 · Cited by 40
Scholtes, R. A., van Baar, M. J. B., Lytvyn, Y., Bjornstad, P., Nieuwdorp, M., Cherney, D. Z. I., & van Raalte, D. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13692 · Cited by 34
Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors
Vaduganathan, M., & Januzzi, J. L. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.026 · Cited by 33
McAlister, F. A., Zheng, Y., Westerhout, C. M., Buse, J. B., Standl, E., McGuire, D. K., de Werf, F. V., Green, J. B., Armstrong, P. W., Holman, R. R., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1958 · Cited by 36
Self-citationChowdhary, A., Thirunavukarasu, S., Joseph, T., Jex, N., Kotha, S., Giannoudi, M., Procter, H., Cash, L., Akkaya, S., Broadbent, D. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.064 · Cited by 32
Carotid plaque imaging profiling in subjects with risk factors (diabetes and hypertension)
Porcu, M., Mannelli, L. D. C., Melis, M., Suri, J. S., Gerosa, C., Cerrone, G., Defazio, G., Faa, G., & Saba, L. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2020.01.13 · Cited by 32
Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis
Luo, X., Yan, C., & Feng, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.004 · Cited by 35
Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes
Rawshani, A., McGuire, D. K., Ömerovic, E., Sattar, N. A., McMurray, J. J. V., Smith, U., Redfors, B., Bergfeldt, L., Eliasson, B., Borén, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-27941-5 · Cited by 34
Self-citationGourdy, P., Schiele, F., Halimi, J., Kownator, S., Hadjadj, S., & Valensi, P. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1227769 · Cited by 34
Gæde, P., Johansen, P., Tikkanen, C. K., Pollock, R. F., Hunt, B., & Malkin, S. J. P. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0630-6 · Cited by 32
Chen, T., Li, Y., Chen, S., Lin, Y., Sun, C., Chen, D., Mao, C., Michael Shengtao, W. U., Chang, C., Chu, P., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01169-3 · Cited by 32
Xu, Z., Chen, P., Wang, L. Y., Yan, J., Yan, X., & Li, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02013-0 · Cited by 32
Lan, N. S. R., Dwivedi, G., Fegan, P. G., Game, F. L., & Hamilton, E. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02527-1 · Cited by 38
Ferreira, J. P., Verma, S., FITCHETT, D. H., Ofstad, A. P., Lauer, S., Zwiener, I., George, J. T., Wanner, C., Zinman, B., & Inzucchi, S. E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01174-6 · Cited by 30
Taskinen, M., Björnson, E., Kahri, J., Söderlund, S., Matikainen, N., Porthan, K., Ainola, M., Hakkarainen, A., Lundbom, N. M. I., Fermanelli, V., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315446 · Cited by 31
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 35
Li, J., Yin, J., Luo, Y., Ma, T., He, L., Xie, H., Li, J., Zhang, G., Cheng, X., & Bai, Y. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109822 · Cited by 30
Cai, J., Yang, Q., Lu, J., Shen, Y., Wang, C., Chen, L., Zhang, L., Lu, W., Zhu, W., Xia, T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac692 · Cited by 30
Karizi, S. R., Armanmehr, F., Azadi, H. G., Zahroodi, H. S., Ghalibaf, A. M., Bazzaz, B. S. F., Abbaspour, M., Boskabadi, S. J., Eslami, S., & Taherzadeh, Z. (2023) · Phytotherapy Research · doi:10.1002/ptr.7674 · Cited by 32
Shen, D., Cai, X., Zhu, Q., Heizhati, M., Hu, J., Song, S., Yang, W., Hong, J., & Li, N. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01303-1 · Cited by 30
Neutrophil aging exacerbates high fat diet induced metabolic alterations
Baragetti, A., Dalt, L. D., Moregola, A., Svecla, M., Terenghi, O., Mattavelli, E., Gaetano, L. N. D., Uboldi, P., Catapano, A. L., & Norata, G. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155576 · Cited by 31
MASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 33
Raggi, P., Senior, P. A., Shahbaz, S., Kaul, P., Hung, R., Coulden, R. A., Yeung, R. O., & Abele, J. T. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311711 · Cited by 29
Monnier, L., Colette, C., Schlienger, J.-L., Bauduceau, B., & Owens, D. R. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.007 · Cited by 29
Stroke in the patient with diabetes (part 1) – Epidemiology, etiology, therapy and prognosis
Bell, D. S. H., & Gonçalves, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108193 · Cited by 29
Coles, B., Zaccardi, F., Hvid, C. A., Davies, M. J., & Khunti, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14218 · Cited by 33
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
Berg, D. D., Wiviott, S. D., Scirica, B. M., Zelniker, T. A., Goodrich, E. L., Jarolı́m, P., Mosenzon, O., Cahn, A., Bhatt, D. L., Leiter, L. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1170 · Cited by 30
Self-citationGoldberg, R. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.011 · Cited by 31
Saigusa, R., Vallejo, J., Gulati, R., Suthahar, S. S. A., Suryawanshi, V., Alimadadi, A., Makings, J., Durant, C. P., Freuchet, A., Roy, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179875 · Cited by 26
Community Health Workers as Trust Builders and Healers: A Cohort Study in Primary Care
Ferrer, R. L., Schlenker, C. G., Cruz, I. I., Noël, P. H., Palmer, R. F., Poursani, R. S., & Jaén, C. R. (2022) · The Annals of Family Medicine · doi:10.1370/afm.2848 · Cited by 33
Blocking MG53 S255 Phosphorylation Protects Diabetic Heart From Ischemic Injury
Lv, F., Wang, Y., Shan, D., Guo, S., Chen, G., Jin, L., Zheng, W., Feng, H., Zeng, X., Zhang, S., et al. (2022) · Circulation Research · doi:10.1161/circresaha.122.321055 · Cited by 29
Tan, J. K., Lim, G. H., Salim, N. N. M., Chia, S. Y., Thumboo, J., & Bee, Y. M. (2023) · Clinical Epidemiology · doi:10.2147/clep.s391749 · Cited by 32
Vági, O. E., Svébis, M. M., Domján, B. A., Körei, A. E., Tesfaye, S. H., Horváth, V. J., Kempler, P., & Tabák, Á. G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1079009 · Cited by 33
[Incisional hernia after surgery for abdominal aortic aneurysm].
Augestad, K. M., Wilsgaard, T., & Solberg, S. K. (2002) · PubMed · Cited by 29
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 37
Walicka, M., Krysiński, A., Rosa, G. R. M. L., Sun, A., Campagna, D., Ciaula, A. D., Dugal, T., Kengne, A. P., Dinh, P. L., Misra, A., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103044 · Cited by 31
Sattar, N. A. (2019) · BMC Medicine · doi:10.1186/s12916-019-1281-1 · Cited by 28
Self-citationVerma, S., Sharma, A., Zinman, B., Ofstad, A. P., FITCHETT, D. H., Brueckmann, M., Wanner, C., Zwiener, I., George, J. T., Inzucchi, S. E., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14015 · Cited by 28
Bruemmer, D., & Nissen, S. E. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000199 · Cited by 30
Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
Jung, C., & Mok, J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.260 · Cited by 28
Su, X., Li, J. H., Gao, Y., Chen, K., Gao, Y., Guo, J. J., Shi, M., Zou, X., Xu, W., Zhao, L., et al. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02461-x · Cited by 31
Phosphate and fibroblast growth factor 23 in diabetes
van der Vaart, A., Yeung, S. M. H., van Dijk, P. R., Bakker, S. J. L., & de Borst, M. H. (2021) · Clinical Science · doi:10.1042/cs20201290 · Cited by 28
Asbaghi, O., Ashtary‐Larky, D., Mousa, A., Kelishadi, M. R., & Moosavian, S. P. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab121 · Cited by 31
Wei, Y., Herzog, K., Ahlqvist, E., Andersson, T., Nyström, T., Zhan, Y., Tuomilehto, J., & Carlsson, S. (2023) · Diabetes Care · doi:10.2337/dc23-0739 · Cited by 30
Green, J. B., Everett, B. M., Ghosh, A., Younes, N., Krause-Steinrauf, H. J., Barzilay, J. I., Desouza, C. V., Inzucchi, S. E., Pokharel, Y., Schade, D. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066604 · Cited by 28
A review of air pollution as a driver of cardiovascular disease risk across the diabetes spectrum
Bonanni, L. J., Wittkopp, S., Long, C., Alemán, J. O., & Newman, J. D. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1321323 · Cited by 28
Singh, P., Sun, J., Cavalera, M., Al-Sharify, D., Matthes, F., Barghouth, M., Tengryd, C., Dunér, P., Persson, A. F., Sundius, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50753-8 · Cited by 27
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 32
Self-citationBlom, D. J., Santos, R. D., Daclin, V., Mercier, F., Ruiz, Á. J., Danchin, N., & on behalf of the ICLPS study group (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871735 · Cited by 29
Association between Hemoglobin A1c and Stroke Risk in Patients with Type 2 Diabetes
Shen, Y., Shi, L., Nauman, E., Katzmarzyk, P. T., Price‐Haywood, E. G., Bazzano, A. N., Nigam, S., & Hu, G. (2020) · Journal of Stroke · doi:10.5853/jos.2019.01704 · Cited by 28
Screen‐detected gallstone disease and risk of liver and pancreatic cancer: The Kailuan Cohort Study
Zhao, X., Wang, N., Sun, Y., Zhu, G., Wang, Y., Wang, Z., Zhang, Y., Cheng, K., Wang, G., Wu, S., et al. (2020) · Liver International · doi:10.1111/liv.14456 · Cited by 27
Collet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 38
Argano, C., Natoli, G., Mularo, S., Nobili, A., Monaco, M. L., Mannucci, P. M., Perticone, F., Pietrangelo, A., & Corrao, S. (2022) · Healthcare · doi:10.3390/healthcare10010086 · Cited by 29
Spaetgens, B., Brouns, S. H. A., Linkens, A. E. M. J. H., Poeze, M., ten Broeke, R. H. M., Brüggemann, R. A. G., Sipers, W. M. W. H., Henry, R. M. A., & Hanssen, N. M. J. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110084 · Cited by 27
Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes
Kamalumpundi, V., Shams, E., Tucker, C., Cheng, L., Peterson, J., Thangavel, S., Ofori, O., & Correia, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115304 · Cited by 27
Pieńkowska, A., Janicka, J., Duda, M., Dzwonnik, K., Lip, K., Mędza, A., Szlagatys‐Sidorkiewicz, A., & Brzeziński, M. (2023) · Nutrients · doi:10.3390/nu15040983 · Cited by 28
Cases, A., Broseta, J. J., Marqués, M., Guldris, S. C., Mauro, J. C. J., Arroyo, R. A., & Ortíz, A. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.011 · Cited by 30
Kishimoto, S., Kinoshita, Y., Matsumoto, T., Maruhashi, T., Kajikawa, M., Matsui, S., Hashimoto, H., Takaeko, Y., Kihara, Y., Chayama, K., et al. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz065 · Cited by 26
Coleman, R. L., Scott, C. A. B., Lang, Z., Bethel, M. A., Tuomilehto, J. O., & Holman, R. R. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0933-y · Cited by 26
German, C. A., Laughey, B., Bertoni, A. G., & Yeboah, J. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107499 · Cited by 26
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
Yang, T., Zhang, L., Yi, L., Feng, H., Li, S., Chen, H., Zhu, J., Zhao, J. H., Zeng, Y., & Liu, H. (2020) · JMIR Medical Informatics · doi:10.2196/15431 · Cited by 26
Cardiac Computed Tomography for Personalized Management of Patients With Type 2 Diabetes Mellitus
Cardoso, R. N., Dudum, R., Ferraro, R., Bittencourt, M. S., Blankstein, R., Blaha, M. J., Nasir, K., Rajagopalan, S., Michos, E. D., Blumenthal, R. S., et al. (2020) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.011365 · Cited by 26
van Gennip, A. C. E., Schram, M. T., Köhler, S., Kroon, A. A., Koster, A., Eussen, S. J. P. M., de Galan, B. E., van Sloten, T. T., & Stehouwer, C. D. A. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00291-4 · Cited by 26
Degree of Joint Risk Factor Control and Incident Heart Failure in Hypertensive Patients
Kou, M., Wang, X., Ma, H., Li, X., Heianza, Y., & Qi, L. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.01.006 · Cited by 26
Ceriello, A., Lucisano, G., Prattichizzo, F., Grotta, R. L., Franzén, S., Guðbjörnsdóttir, S., Eliasson, B., & Nicolucci, A. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad072 · Cited by 27
Self-citationExtrinsic and intrinsic modulators of inflammation-resolution signaling in heart failure
Rao, A., Gupta, A., Kain, V., & Halade, G. V. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00276.2023 · Cited by 27
Liu, J., Tarasenko, L. C., Terra, S. G., Huyck, S. B., Wu, L., Pong, A., Calle, R. A., Gallo, S., Darekar, A., & Mancuso, J. P. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119842513 · Cited by 25
Olson, K. L., Neiberg, R. H., Espeland, M. A., Johnson, K., Knowler, W. C., Pi‐Sunyer, X., Staiano, A. E., Wagenknecht, L. E., & Wing, R. R. (2020) · Obesity · doi:10.1002/oby.22942 · Cited by 27
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 25
Myhre, P. L., Lyngbakken, M. N., Berge, T., Røysland, R., Aagaard, E. N., Pervez, O., Kvisvik, B., Brynildsen, J., Norseth, J., Tveit, A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020447 · Cited by 25
Guía ESC 2021 sobre estimulación cardiaca y terapia de resincronización
Glikson, M., Nielsen, J. C., Kronborg, M. B., Michowitz, Y., Auricchio, A., Barbash, I. M., Barrabés, J. A., Boriani, G., Braunschweig, F., Brignole, M., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.025 · Cited by 28
Schubert, J. R., Lindahl, B., Melhus, H., Renlund, H., Leósdóttir, M., Yari, A., Ueda, P., Jernberg, T., & Hagström, E. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13656 · Cited by 25
Impact of facility type and volume in low-grade glioma outcomes
Zhu, P., Du, X. L., Blanco, A. I., Ballester, L. Y., Tandon, N., Berger, M. S., Zhu, J., & Esquenazi, Y. (2019) · Journal of neurosurgery · doi:10.3171/2019.6.jns19409 · Cited by 25
Li, Y., Yao, Z., Yue, W., Zhang, C., Gao, S., & Wang, C. (2020) · Sensors · doi:10.3390/s20061565 · Cited by 25
Milajerdi, A., Ostadmohammadi, V., Amirjani, S., Kolahdooz, F., & Asemi, Z. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02236-9 · Cited by 24
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- Uppsala University (SE)
- From the Department of Molecular and Clinical Medicine, Institute of Medicine (Aidin Rawshani, Araz Rawshani, B.E., A. Rosengren, S.G.), and the Health Metrics Unit, Sahlgrenska Academy (S.F.), University of Gothenburg, and the Swedish National Diabetes Register, Center of Registers in Region (Aidin Rawshani, Araz Rawshani, S.F., B.E., A.-M.S., M.M., S.G.), Gothenburg, and the Department of Public Health and Caring Sciences–Geriatrics, Uppsala University, and the Swedish Medical Products Agency,...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-16
- Volume
- 379
- Issue
- 7
- Pages
- 633-644
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2887185538
- Cited by
- 1,475
- References
- 22
- Citations by year
- 2026: 158 · 2025: 172 · 2024: 178 · 2023: 175 · 2022: 197 · 2021: 219 · 2020: 210 · 2019: 141 · 2018: 20
- FWCI
- 116.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk factors, mortality, acute myocardial infarction, stroke, heart failure hospitalization, HbA1c, LDL cholesterol, albuminuria, smoking, blood pressure, Swedish National Diabetes Register, matched cohort comparison
- MeSH terms
- Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypercholesterolemia, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Smoking, Sweden, Cohort Studies, Body Mass Index, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
